Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
0.9950
-0.0150 (-1.49%)
Feb 24, 2026, 4:00 PM EST - Market closed
Cocrystal Pharma Employees
Cocrystal Pharma had 11 employees as of December 31, 2024. The number of employees decreased by 1 or -8.33% compared to the previous year.
Employees
11
Change (1Y)
-1
Growth (1Y)
-8.33%
Revenue / Employee
n/a
Profits / Employee
-$879,182
Market Cap
13.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 11 | -1 | -8.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | 0 | - |
| Dec 31, 2020 | 13 | 2 | 18.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| BioLineRx | 28 |
| BioCardia | 20 |
| Edesa Biotech | 17 |
| Quantum BioPharma | 17 |
| IN8bio | 17 |
| NewcelX | 15 |
| Cellectar Biosciences | 11 |
COCP News
- 5 days ago - Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 - GlobeNewsWire
- 2 months ago - Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus - GlobeNewsWire
- 3 months ago - Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference - GlobeNewsWire
- 3 months ago - Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program - GlobeNewsWire
- 5 months ago - Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference - GlobeNewsWire
- 5 months ago - Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire